Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 811-829 , October 2008

Autoinflammatory diseases

  • Isabelle Touitou, MD, PhD (Professor of Genetics)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +33 4 67 33 58 59; Fax: +33 4 67 33 58 67.

References 

  1. McDermott MF, Aksentijevich I. The autoinflammatory syndromes. Current Opinion in Allergy and Clinical Immunology. 2002;2(6):511–516
  2. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Current Opinion in Rheumatology. 2003;15(1):61–69
  3. Brydges S, Kastner DL. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Current Topics in Microbiology and Immunology. 2006;305:127–160
  4. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology. 2007;81(1):1–5
  5. Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends in Immunology. 2006;27(8):352–357
  6. Leber JH, Crimmins GT, Raghavan S, et al. Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen. PLoS pathogens. 2008;4(1):e6
  7. McDermott MF. A common pathway in periodic fever syndromes. Trends in Immunology. 2004;25(9):457–460
  8. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nature Genetics. 2001;29(3):301–305
  9. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. American Journal of Human Genetics. 2002;71(1):198–203
  10. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular Cell. 2002;10(2):417–426
  11. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319–325
  12. The French FMF Consortium . A candidate gene for familial Mediterranean fever. Nature Genetics. 1997;17(1):25–31
  13. The International FMF Consortium . Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807
  14. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(26):9982–9987
  15. Dowds TA, Masumoto J, Chen FF, et al. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochemical and Biophysical Research Communications. 2003;302(3):575–580
  16. Papin S, Cuenin S, Agostini L, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007;
  17. Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(23):13501–13506
  18. Jeru I, Duquesnoy P, Fernandes-Alnemri T, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(5):1614–1619
  19. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nature Genetics. 1999;22(2):178–181
  20. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nature Genetics. 1999;22(2):175–177
  21. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cellular and Molecular Life Sciences. 2003;60(6):1118–1134
  22. Mandey SH, Kuijk LM, Frenkel J, Waterham HR. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis and Rheumatism. 2006;54(11):3690–3695
  23. Hoffmann GF, Wiesmann UN, Brendel S, et al. Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway in fibroblasts from patients with mevalonate kinase deficiency. Pediatric Research. 1997;41(4 Pt 1):541–546
  24. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133–144
  25. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nature Genetics. 2001;29(1):19–20
  26. Pullen SS, Labadia ME, Ingraham RH, et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry. 1999;38(31):10168–10177
  27. Ogura H, Tsukumo Y, Sugimoto H, et al. Ectodomain shedding of TNF receptor 1 induced by protein synthesis inhibitors regulates TNF-alpha-mediated activation of NF-kappaB and caspase-8. Experimental Cell Research. 2008;314(6):1406–1414
  28. Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. American Journal of Human Genetics. 2001;69(2):301–314
  29. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2007;292(1):R86–R98
  30. Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Reviews in Molecular Medicine. 2005;7(22):1–18
  31. Gul A. Behcet's disease as an autoinflammatory disorder. Current Drug Targets. Inflammation and Allergy. 2005;4(1):81–83
  32. Gul A. Behcet's disease: an update on the pathogenesis. Clinical and Experimental Rheumatology. 2001;19(5 Suppl. 24):S6–S12
  33. Abdel-Aziz AH, Fairburn EA. Familial Behcet's syndrome. Cutis. 1978;21(5):649–652
  34. Kera J, Mizuki N, Ota M, et al. Significant associations of HLA-B*5101 and B*5108, and lack of association of class II alleles with Behcet's disease in Italian patients. Tissue Antigens. 1999;54(6):565–571
  35. Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(4):1298–1303
  36. Molinari N, Kone Paut I, Manna R, et al. Identification of an autosomal recessive mode of inheritance in paediatric Behcet's families by segregation analysis. American Journal of Medical Genetics. Part A. 2003;122(2):115–118
  37. de Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?. Arthritis and Rheumatism. 2005;52(3):687–693
  38. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. The Journal of Experimental Medicine. 2005;201(9):1479–1486
  39. Grateau G, Jeru I, Rouaghe S, et al. Amyloidosis and autoinflammatory syndromes. Current Drug Targets. Inflammation and Allergy. 2005;4(1):57–65
  40. Aksentijevich I, Putnam CD, Remmers EF, et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis and Rheumatism. 2007;56(4):1273–1285
  41. Heller H, Sohar E, Pras M. Ethnic distribution and amyloidosis in familial Mediterranean fever (FMF). Pathologia Et Microbiologia. 1961;24:718–723
  42. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis and Rheumatism. 1997;40(10):1879–1885
  43. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. European Journal of Human Genetics. 2001;9(7):473–483
  44. Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial mediterranean fever. Arthritis and Rheumatism. 2007;56(5):1706–1712
  45. Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. The New England Journal of Medicine. 1986;314(16):1001–1005
  46. Tunca M, Akar S, Soyturk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clinical and Experimental Rheumatology. 2004;22(4 Suppl. 34):S37–S40
  47. Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatology International. 2006;
  48. Seyahi E, Ozdogan H, Masatlioglu S, Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clinical and Experimental Rheumatology. 2002;20(4 Suppl. 26):S43–S44
  49. Tallon B, Corkill M. Peculiarities of PAPA syndrome. Rheumatology (Oxford, England). 2006;45(9):1140–1143
  50. Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatric Dermatology. 2005;22(3):262–265
  51. Houten SM, Frenkel J, Kuis W, et al. Molecular basis of classical mevalonic aciduria and the hyperimmunoglobulinaemia D and periodic fever syndrome: high frequency of 3 mutations in the mevalonate kinase gene. Journal of Inherited Metabolic Disease. 2000;23(4):367–370
  52. Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet Journal of Rare Diseases. 2006;1:13
  53. Houten SM, Wanders RJ, Waterham HR. Biochemical and genetic aspects of mevalonate kinase and its deficiency. Biochimica Et Biophysica Acta. 2000;1529(1–3):19–32
  54. Hoffmann GF, Brendel SU, Scharfschwerdt SR, et al. Mevalonate kinase assay using DEAE-cellulose column chromatography for first-trimester prenatal diagnosis and complementation analysis in mevalonic aciduria. Journal of Inherited Metabolic Disease. 1992;15(5):738–746
  55. Ammouri W, Cuisset L, Rouaghe S, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford, England). 2007;46(10):1597–1600
  56. Lachmann HJ, Goodman HJ, Andrews PA, et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. Arthritis and Rheumatism. 2006;54(6):2010–2014
  57. Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clinical Pharmacology and Therapeutics. 2004;75(5):476–483
  58. Bodar EJ, van der Hilst JC, Drenth JP, et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. The Netherlands Journal of Medicine. 2005;63(7):260–264
  59. Drenth JP, Vonk AG, Simon A, et al. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. The Journal of Pharmacology and Experimental Therapeutics. 2001;298(3):1221–1226
  60. Williamson LM, Hull D, Mehta R, et al. Familial Hibernian fever. The Quarterly Journal of Medicine. 1982;51(204):469–480
  61. Ravet N, Rouaghe S, Dode C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Annals of the Rheumatic Diseases. 2006;65(9):1158–1162
  62. Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford, England). 2003;42(2):235–239
  63. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis and Rheumatism. 2008;58(5):1516–1520
  64. Marshall GS, Edwards KM, Lawton AR. PFAPA syndrome. The Pediatric Infectious Disease Journal. 1989;8(9):658–659
  65. Wong KK, Finlay JC, Moxham JP. Role of Tonsillectomy in PFAPA Syndrome. Archives of Otolaryngology Head & Neck Surgery. 2008;134(1):16–19
  66. Eiling E, Schroder JO, Gross WL, et al. The Schnitzler syndrome: Chronic urticaria and monoclonal gammopathy – an autoinflammatory syndrome?. Journal der Deutschen Dermatologischen Gesellschaft. 2008;
  67. Wastiaux H, Barbarot S, Gagey-Caron V, et al. Schnitzler syndrome: a dramatic improvement with anakinra. Journal of the European Academy of Dermatology and Venereology. 2008;
  68. Miyachi Y, Taniguchi S, Ozaki M, Horio T. Colchicine in the treatment of the cutaneous manifestations of Behcet's disease. The British Journal of Dermatology. 1981;104(1):67–69
  69. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 1998;128(6):443–450
  70. Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha- interferon. Archives for Dermatological Research. 1986;278(4):335–336
  71. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. The New England Journal of Medicine. 1999;341(17):1284–1291
  72. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Seminars in Arthritis and Rheumatism. 2004;33(5):311–319
  73. Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford, England). 2007;46(10):1570–1573
  74. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. The Journal of Rheumatology. 2005;32(1):98–105
  75. Milhavet F, Cuisset L, Hoffman HM, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Human Mutation. 2008;29(6):803–808
  76. Touitou I, Magne X, Molinari N, et al. MEFV mutations in Behcet's disease. Human Mutation. 2000;16(3):271–272
  77. Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clinical and Experimental Rheumatology. 2003;21(4 Suppl. 30):S35–S37
  78. Amoura Z, Dode C, Hue S, et al. Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis and Rheumatism. 2005;52(2):608–611
  79. Kone-Paut I, Sanchez E, Le Quellec A, et al. Autoinflammatory gene mutations in Behcet's disease. Annals of the Rheumatic Diseases. 2007;
  80. Drewe E, Huggins ML, Morgan AG, et al. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford, England). 2004;43(11):1405–1408
  81. Takada K, Aksentijevich I, Mahadevan V, et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis and Rheumatism. 2003;48(9):2645–2651
  82. Cortis E, De Benedetti F, Insalaco A, et al. Abnormal production of tumor necrosis factor (TNF) – alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome. [corrected] The Journal of Pediatrics. 2004;145(6):851–855
  83. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358(9278):295–296
  84. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis and Rheumatism. 2003;48(1):218–226
  85. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis and Rheumatism. 2004;50(2):607–612
  86. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. European Journal of Pediatrics. 2008;167(6):695–696
  87. Milledge J, Shaw PJ, Mansour A, et al. Allogenic bone marrow transplantation: cure for familial Mediterranean fever. Blood. 2002;100(3):774–777
  88. Touitou I. Should patients with FMF undergo BMT?. Blood. 2003;101(3):1205;author reply -6
  89. Neven B, Valayannopoulos V, Quartier P, et al. Allogeneic bone marrow transplantation in mevalonic aciduria. The New England Journal of Medicine. 2007;356(26):2700–2703

PII: S1521-6942(08)00096-X

doi: 10.1016/j.berh.2008.08.009

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 811-829 , October 2008

Article Tools

* Image Usage & Resolution